The forecast for anxiolytic medicine sales in Canada, beginning from a 2023 base level of 107.5 million USD, indicates a slightly declining trend over the 2024 to 2028 period. Starting at 106.8 million USD in 2024, sales are expected to decrease incrementally each year, reaching 104.2 million USD by 2028. This translates to an approximate year-on-year decrease: -0.8% from 2024 to 2025, -0.7% from 2025 to 2026, -0.6% from 2026 to 2027, and -0.4% from 2027 to 2028. The compound annual growth rate (CAGR) over these five years is approximately -0.6%.
Future trends to watch for include changes in regulation and public perception regarding anxiolytic medications, as well as advancements in alternative therapies that may influence demand. Additionally, shifts in societal mental health needs and the healthcare sector's adaptation to these needs could impact sales trajectories.
